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Glycogen synthase kinase 3
Prion disease
LithiumPrion protein (PrP) mislocalized in the cytosol has been presumed to be the toxic entity responsible for the neu-
rodegenerative process in transmissible spongiform encephalopathies (TSE), also called prion diseases. The
mechanism underlying the neurotoxicity of cytosolic PrP (cytoPrP) remains, however, unresolved. In this study
we analyze toxic effects of the cell-penetrating PrP fragment, PrP1–30 — encompassing residues responsible
for binding and aggregation of tubulin.We have found that intracellularly localized PrP1-30 disassembles micro-
tubular cytoskeleton of primary neurons, which leads to the loss of neurites and, eventually, necrotic cell death.
Accordingly, stabilization ofmicrotubules by taxol reduced deleterious effects of cytosolic PrP1–30. Furthermore,
we have demonstrated that decreased phosphorylation level of microtubule-associated proteins (MAPs), which
also increases stability of microtubular cytoskeleton, protects neurons from the toxic effects of PrP1–30.
CHIR98014 and LiCl— inhibitors of glycogen synthase kinase 3 (GSK-3), amajor kinase responsible for phosphor-
ylation of MAPs, inhibited PrP1-30-induced disruption of microtubular cytoskeleton and increased viability of
peptide-treatedneurons.Wehave also shown that theN-terminal fragment of cytoPrPmay cause the loss of den-
dritic spines. PrP1–30-induced changes at the level of spines have also been prevented by stabilization of micro-
tubules by taxol as well as LiCl. These observations indicate that the neurotoxicity of cytoPrP is tightly linked to
the disruption of microtubular cytoskeleton. Importantly, this study implies that lithium, the commonly used
mood stabilizer, may be a promising therapeutic agent in TSE, particularly in case of the disease forms associated
with accumulation of cytoPrP.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Cellular prion protein (PrPC) in its misfolded form, denoted PrPSc, is
known as a key molecule in the pathogenesis of TSE or even the sole in-
fectious particle in these unique neurodegenerative diseases [1]. Despite
many leads, the physiological function of PrPC, the mechanism of its
conversion into PrPSc and the nature of the neurotoxic process in TSE re-
main unclear. PrPC is a highly conserved glycoprotein, constitutively
expressed in the nervous system and, at lower levels, in many
extraneural tissues of healthy organisms [2]. In its precursor form PrPC
is composed of 253 aa residues (human PrP). The 22 N-terminal andn protein with the C-terminus
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nski).23 C-terminal residues constitute signal sequences that are responsible
for proper sorting/localization and processing of PrP and are usually
cleaved off posttranslationally. The N-terminal signal sequence guides
translocation into the lumen of endoplasmic reticulum (ER), whereas
the C-terminal sequence comprises a signal for the attachment of
glycosylphosphatidylinositol moiety (GPI) [3,4]. Normally, the so-
called secreted PrPC is transported and attached to the surface of the
plasma membrane via GPI anchor. PrP can also be detected inside the
cell, though at a very low level. Two transmembranal forms with N- or
C-terminus residing inside the ER lumen, denoted as NtmPrP and
CtmPrP, respectively, have been identiﬁed [5–8]. While CtmPrP has been
detected in familial form of TSE, the former topological form has been
observed only in vitro. CtmPrP retains its N-terminal signal sequence
which faces, along with N-terminal part of the molecule, the cytosolic
environment. There is also a cytosolic fraction of prion protein, denoted
as cytoPrP, retaining both signal peptides, which is not associated with
the ER compartment. Increased intracellular localization of PrP usually
results from pointmutations in the PrP-coding gene, ER stress or inhibi-
tion of proteasome by PrPSc as well as aggregated PrP [rev. in [9]]. Ele-
vated concentration of cytosolic forms of PrP is observed in familial
TSE and experimental models of the disease [[5,7,8], rev. in: [9,10]]. It
has been demonstrated that the mislocalized PrP may bind to and
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[rev. in [11]]. CytoPrP interacts with cytosolic proteins such as tubulin,
Bcl-2 and ubiquitin ligase mahogunin, leading to loss of their functions
[12–14]. These excessive or non-physiological interactions may under-
lay the molecular mechanism of cytoPrP neurotoxicity in TSE [rev. in:
[9,11]]. For example, direct interaction between PrP and tubulin induces
tubulin oligomerization/aggregation and inhibits microtubule assembly
[12,15]. It has also been proposed that at very low, physiological concen-
trations in the cytosol, PrP may play a role of the modulator of microtu-
bule dynamics [rev. in [11]]. We have found that, adjacent to the
N-terminal signal sequence, residues 23–32 constitute major tubulin
binding site responsible for tubulin aggregation and PrP peptide 1–30
causes disassembly of themicrotubular cytoskeleton of epithelial cancer
cells [16]. Accordingly, earlier ultrastructural studies of TSE brains
revealed loss of microtubules in dendrites [17]. Furthermore,
microtubule-associated proteins (MAPs) such as Tau protein, which
are responsible for stabilization of the cytoskeleton may protect cells
from toxic effect of intracellularly mislocalized PrP [18]. Phosphoryla-
tion of Tau, causing its dissociation from tubulin and attenuation of
microtubule-stabilizing function, facilitates PrP-induced aggregation of
tubulin. Noteworthy, hyperphosphorylated Tau is frequently detected
in TSE and amyloidogenic PrP fragment 106–126 has been demonstrat-
ed to induce phosphorylation of MAPs [19–23]. Hence, we hypothesize
that stabilization of themicrotubular cytoskeletonmay be an important
target during therapy of the TSE forms associated with increased accu-
mulation of cytoPrP. In this report, we verify the above hypothesis and
demonstrate the impact of microtubule stabilization on neurotoxicity
of the N-terminal fragment of cytoPrP encompassing residues responsi-
ble for aggregation of tubulin. To this end we employed taxol, a drug
known to directly bind to tubulin and promote microtubule assembly
[24], as well as inhibitors of GSK-3, which is a major kinase responsible
for phosphorylation of MAPs and reduced stability of the microtubular
cytoskeleton [rev. in [25]].
2. Material and methods
2.1. Peptide synthesis
Peptide MANLGYWLLALFVTMWTDVGLCKKRPKPGG-NH2 (PrP1–30)
corresponding to the mouse PrP sequence 1–30, was synthesized by
Proteogenix (Schiltigheim, France). Biotin was attached to the N-
terminus of the peptide via amino-hexanoyl linker. Additionally,
PrP1–30 lacking biotin was synthesized. Peptides KKRPKPGGWN
(PrP23–32) and KKRPKPGGWNTGGSRYPGQGSPGGNRYP (PrP23–50;
containing N-terminally attached biotin) were synthesized by EZBiolab
(Westﬁeld, USA) and Proteogenix, respectively. The peptides were of
95% purity as determined by HPLC and mass spectrometry analyses.
PrP1–30 was dissolved in deionized water and stored at−70 °C.
2.2. Tubulin puriﬁcation
Tubulin was puriﬁed from porcine brains according to the modiﬁed
method of Mandelkow and colleagues [26], described in details in [12].
Tubulin aliquots were stored at−70 °C in a buffer composed of 2 mM
EGTA, 0.1 mM EDTA, 2 mM DTT, 1 mM ATP and 100 mM PIPES pH 6.9.
Just before experiments the preparations were centrifuged at
22,000 ×g, for 20 min, at 4 °C, and obtained supernatants were used.
2.3. Cell culture
Cortical and hippocampal primary neuronal cells were prepared
from embryos (E-18 to E-19) of Wistar rats. Pregnant animals were
anesthetized with isoﬂurane and killed by decapitation in accordance
with the ethical guidelines approved by the Local Ethical Committee
on Animal Research of the Nencki Institute. Embryo brains were re-
moved and the cerebral cortex, and hippocampi were dissected on icein Hank's balanced salt solution (HBSS, Gibco/Life Technologies, UK)
containing 10mMHEPES pH 7.3, 100 U penicillin, and 0.1mg/ml strep-
tomycin (Sigma). Tissue was rinsed 3 times with cold HBSS and subse-
quently incubated for 20minwith 2.5% trypsin (Gibco) inHBSS, at 37 °C.
The cultures were rinsed three times with warm (37 °C) HBSS and then
dissociated by pipetting, and plated onto poly-D-lysine-coated 96-well
plates (Becton Dickinson, UK), 18-mm poly-D-lysine-coated glass
coverslips (Neuvitro, USA) or 60-mm culture dishes (Corning, USA)
covered with poly-D-lysine (70–100 kDa, Sigma). The cell suspension
was plated at the density of 4 × 104 cells/well, 6 × 104 cells/coverslip
or 170 × 104 cells/dish, and cultured in Neurobasal medium (Gibco)
supplemented with 100 U penicillin, 0.1 mg/ml streptomycin, 0.5 mM
L-glutamine (Sigma), and 2% B27 (Gibco). The culturesweremaintained
at 37 °C in a humidiﬁed incubator with 5% CO2 and used 7 or 21 days
after plating. Before incubationswith PrP1–30 the cells were pretreated
for 1 hwith one of the following compounds: taxol (Paclitaxel, Sigma; in
DMSO), CHIR98014 (Axon Medchem, Netherlands; in DMSO) or LiCl
(Sigma). Subsequently, the cells were co-incubated for 12 h with the
peptide and appropriate compound. To induce apoptotic cell death, the
7-day cultures were treated for 12 h with 25 nM doxorubicin (Sigma).
To visualize dendritic spines, cortical neurons (21 days after plating)
were transfected with plasmid encoding red ﬂuorescent protein
(RFP) under the control of actin promoter (pCX-mRFP1, a gift from
A. K. Hadjantonakis [27]; Addgene plasmid # 32600) employing
lipofectamine-based procedure (Lipofectamine 2000, Invitrogen, USA)
according to the manufacturer's instruction. Density of the spines was
analyzed on day 23 (after plating).
2.4. Viability assay
Cell viability was assessed using lactate dehydrogenase (LDH) assay
(Promega) according to themanufacturer's instruction. The level of LDH
released by dying cells was determined in the culture medium. Absor-
bance at 490 nm was measured in a plate reader (Sunrise FO 39300,
Tecan, Switzerland) and normalized against the medium. Data are
expressed as the ratio of the absorbance for treated and control cells.
Additionally, the number of viable cells was determined using trypan
blue exclusion test. The neurons were detached from culture dish with
0.25% trypsin–EDTA and incubated with 0.2% trypan blue. Dead cells
(stained with the dye) and viable cells (unstained) were enumerated
by means of Automated Cell Counter TC10 (BioRad, Hercules, USA).
2.5. Pull-down assay
Magnetic beads (50 μl of slurry) covalently coated with streptavidin
(Genscript, USA)were incubated for 1 h on icewith orwithout PrP1–30
containing biotin at the N-terminus (50 μl of 540 μM peptide), in PBS
supplemented with 1 mM PMSF. Uncoupled peptide was removed by
extensive washing with PBS. Primary cortical neurons were lysed for
20 min on ice in the Cell Lysis Buffer supplemented with 10 mM NaF
and Protease Inhibitor Cocktail (Complete Mini EDTA-free, Roche,
Switzerland). The lysates were centrifuged for 15 min, at 18,000 ×g, at
4 °C, and subsequently protein concentration in the supernatants was
determined by the Bradford method [28]. Equal volumes of the super-
natants (200 μl of 1.2 mg/ml total protein) were incubated for 10 min
on ice with the beads containing immobilized PrP1–30 or without the
peptide. The beadswerewashedwith 5 volumes of PBS. Bound fractions
were eluted by 5-min boiling of the beads in 20 μl of SDS-PAGE sample
buffer (25% glycerol, 2% SDS, 0.1% bromophenol blue, 14.4 mM
β-mercaptoethanol, 60 mM Tris–HCl, pH 6.8).
2.6. Light scattering
Microtubule assembly and tubulin aggregation were assessed by
turbidity measurements at 350 nm as previously described [15], under
Fig. 1. PrP1–30 binds to tubulin in the lysates of neuronal cells. In pull-down assay equal
volumes of lysates of primary cortical neurons were applied onto streptavidin beads
with or without immobilized PrP1–30 (containing biotin attached to the N-terminus).
(A) Samples of the lysate (lane 0), ﬂow-through fractions (lane 1), fractions obtained
upon washing (lane 2) and fractions bound to the beads (lane 3) were analyzed by
Western blotting using antibodies against β-tubulin and β-actin. In (B), Ponceau-stained
blot is shown and band corresponding to tubulin is indicated by an arrow. Representative
blots for three independent experiments are presented.
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tubulin at 2 mg/ml (40 μM) was incubated with or without PrP1–30 in
the polymerization buffer containing 20 μM taxol, 1 mM GTP, 16 mM
MgCl2, 10% (w/v) glycerol and 10 mM sodium phosphate buffer
pH 7.0. Monitoring of the turbidity was initiated immediately after the
addition of tubulin to the cuvette and carried out at 37 °C.
2.7. Transmission electron microscopy
Tubulin samples analyzed by light scattering were also subjected to
electron microscopy. After 20 min of incubation, as described above,
10-μl samples were placed for 40 s on copper grids (400 mesh, Sigma)
covered with collodion (SPI Supplies, West Chester, PA, USA) and car-
bon. The grids were negatively stained with 2% (w/v) uranyl acetate
(SPI Supplies) for 25 s. The preparations were examined in a JEM-
1400 transmission electron microscope (JEOL Co., Japan), and images
were acquired with a digital camera (CCD MORADA, SiS-Olympus,
Germany).
2.8. Immunocytochemistry
Cells grown on the coverslips were ﬁxed with 3% paraformaldehyde
in PBS/5% sucrose for 10 min at 25 °C. Then the cells were treated with
50 mM NH4Cl in PBS for 10 min and permeabilized with 0.1% Triton X-
100 in PBS for 10 min at 25 °C. The coverslips were blocked by 2% BSA,
1.5% horse serum and 0.1% Triton X-100 in PBS for 10 min at 25 °C,
and subsequently incubated with primary antibodies for 20 h at 4 °C.
Antibodies against β-tubulin (T0198, Sigma; diluted at 1:500), Tau
protein (Tau-5, Calbiochem/Millipore, USA; 1:500), MAP2 (4542, Cell
Signaling, USA; 1:50) and caspase-3 activated by cleavage at Asp175
(9661, Cell Signaling; 1:400) were used. Synapses were detected with
antibodies against synaptophysin I (101 004, Synaptic Systems,
Germany; 1:200). Subsequently, the coverslips were washed 3 times
with 0.05% Triton X-100 in PBS followed by 1-h incubation at 25 °C
with appropriate secondary antibodies conjugated with either Alexa
546, Alexa 488 or Alexa 647 (Invitrogen), diluted at 1:500. PrP1–30
and PrP23–50, containing biotin tag, were detected with streptavidin–
FITC (Sigma; 1:100). The coverslips were then washed twice with
0.05% Triton X-100 in PBS and once with PBS, and mounted on glass
slides. Additionally, DNA was stained with DAPI (Vectashield Mounting
Medium, Vector Laboratories, USA). The cells were examined under
confocal microscope Leica TCS SP8 or Zeiss LSM780 and ﬂuorescent
microscope Nicon Eclipse Ti. The microscopic analysis was repeated
multiple times with representative images shown.
2.9. Electrophoresis
SDS-PAGE separations were performed on 10% gels according to
Laemmli procedure [29]. To improve separation of Taumolecules differ-
ing in phosphorylation status, the electrophoresis was carried out until
the 37 kDa marker reached the edge of the separating gel.
2.10. Western blotting
Cells grown on the culture dishes were washed with PBS and lysed
in the Cell Lysis Buffer as described above. The lysates were cleared by
centrifugation at 18,000 ×g for 15 min, at 4 °C. Protein concentration
in obtained supernatants was determined by the Bradford method
[28]. After electrophoretic separation, proteins were electrotransferred
onto nitrocellulose membrane (Amersham Biosciences, USA) in a
standard transfer bufferwith 0.05% SDS. The blots were probedwith an-
tibodies against Tau (Tau-5, Calbiochem; diluted at 1:5000), β-tubulin
(T0198, Sigma; 1:1000), MAP2 (M4403, Sigma; 1:2000), MAP2 phos-
phorylated on Thr 1620 and 1623 (4544, Cell Signaling; 1:1000) or
LC3 (L7543, Sigma; 1:500). Then, secondary antibodies AP307P
(Millipore) conjugated with horseradish peroxidase (HRP) diluted at1:5000 were used. β-actin was detected by antibodies A3854 (Sigma;
1:40,000) conjugatedwith HRP. Antigenswere visualized by incubation
of the blots with a chemiluminescent HRP substrate (Millipore) follow-
ed by exposition to X-ray ﬁlms (Fuji, Japan).
3. Results
To understand themolecularmechanismof neurotoxicity of cytosol-
ic PrP, we have employed a cell-penetrating peptide encompassing res-
idues 1–30 of themouse protein (PrP1–30) as a model. Similar peptide,
namely PrP1–28has been previously demonstrated to localize to the cy-
toplasm of cultured cancer cells [30]. PrP1–30 is composed of signal se-
quence 1–22 and residues 23–30, identiﬁed as a major binding site for
tubulin on the PrP molecule, responsible for inhibition of microtubule
assembly [16]. Noteworthy, cytosolic forms of PrP (both CtmPrP and
cytoPrP) retain the N-terminal signal sequence [rev. in: [9,10]]. In this
study, we decided to dissect mechanism of neurotoxicity of PrP1–30
in the culture of primary neuronal cells, isolated from brains of rat em-
bryos. Importantly, these embryonic neurons are characterized by in-
creased level of MAPs phosphorylation which resembles, in this
regard, the picture observed in TSE, where hyperphosphorylated Tau
is frequently detected. Detailed analyses have shown elevatedGSK-3 ac-
tivity and increased phosphorylation of Tau in the developing rat brain,
which peaked around postnatal day 10 [31,32]. Therefore we have cho-
sen primary neurons as a model system to analyze effect of phosphory-
lation of MAPs on neurotoxicity of cytoPrP.
First we checked whether PrP1–30 can interact with tubulin in the
lysates of primary neurons. To this end we performed pull-down assay
employing the peptide containing biotin, attached via amino-hexanoyl
spacer to its N-terminus. This peptidewas immobilized on themagnetic
beads coated with streptavidin. The lysate of cortical neurons (cultured
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streptavidin beads with or without immobilized PrP1–30. As it is
demonstrated in Fig. 1A, tubulin was bound to the beads containing
PrP1–30, whereas it was not retained on the beads lacking the peptide.
Tubulin was a major protein found in the PrP1–30-bound fraction as
indicated by protein-stained blot (Ponceau, Fig. 1B, lane 3). Importantly,
another abundant cytoskeletal protein — β-actin has not been detected
in the peptide-bound fraction (Fig. 1A), implying selectivity of the
interaction.
Previously, we have demonstrated that full-length PrP as well as its
N-terminal fragments induce oligomerization/aggregation of tubulin
thereby, leading to inhibition of microtubule formation [15,16]. To
check whether PrP1–30 (containing N-terminally attached biotin)
retains ability to affect microtubule assembly, we performed standard
turbidity measurements for tubulin samples incubated with the pep-
tide, at the conditions promoting microtubule formation. The measure-
ments were performed spectrophotometrically at 350 nm wavelength
to detect light-scattering assemblies of tubulin, either native microtu-
bules or dysfunctional aggregates. As demonstrated in Fig. 2A, PrP1–
30 induced concentration-dependent increase in the turbidity of tubulin
samples. In line with the previous observations obtained for other PrP
fragments encompassing residues 23–30, electron microscopic analysis
of these samples revealed that PrP1–30 induced aggregation of tubulin
accompanied by inhibition of formation of microtubules (Fig. 2B).Fig. 2. PrP1–30 induces aggregation of tubulin and inhibits microtubule formation. In (A),
changes in the turbidity of tubulin samples were monitored spectrophotometrically at
350 nm. Tubulin (40 μM) was incubated alone or with increasing concentrations of
PrP1–30 (5, 10, 20 μM), at the conditions promoting microtubule formation. Turbidity of
PrP1–30 (20 μM) incubated alone is also shown. In (B), morphology of tubulin structures
formedupon20-min incubation in thepresence or absence of the peptidewas analyzedby
TEM. Micrographs of the samples of tubulin (40 μM) incubated alone or with PrP1–30
(20 μM) are presented. Note, that the increase in the turbidity of tubulin samples induced
by the peptide (A) results from tubulin aggregation and is accompanied by a reduced
number of microtubules (B). Representative results from at least three independent
repeats are shown.Similar results were obtained for PrP1–30 lacking biotin (see Supple-
mentary data, Fig. S1).
Subsequently, we checked whether PrP1–30 can penetrate cell
membrane of neurons and inﬂuence morphology of their microtubular
cytoskeleton. The primary cortical neurons isolated from brains of rat
embryos (cultured for 7 days) were incubated for 12 h with 20 μM
PrP1–30 and subsequently ﬁxed for confocal microscopy. Owing to bio-
tin attached to the N-terminus of the peptide, we were able to visualize
its cellular localization employing ﬂuorescently labeled streptavidin. As
expected, PrP1–30 accumulated abundantly in the cytosol of neurons
already after 12-h incubation with the cell culture (Fig. 3C–E). In con-
trast, peptide corresponding to PrP residues 23–50was not internalized
by neurons, indicating a crucial role of the signal sequence 1–22 for the
cytosolic localization (Fig. 3H–J). The intracellular accumulation of
PrP1–30 was accompanied by apparent alterations in the microtubular
network (Fig. 3). This cytoskeleton was largely disassembled and tubu-
lin formed aggregates concentrated in a dotted pattern in the PrP1–30-
treated neurons. Disruption of the microtubular cytoskeleton was
reﬂected by changes in the morphology of neurons, in particular by
shortening and loss of neurites (Fig. 3B–E). PrP1–30-treated cells usual-
ly retained only one long, thick neurite which was MAP2-positive and
thus bore feature of dendrites (Supplementary data, Fig. S2). We were
unable to ﬁnd axonal neurites (stained with anti-Tau antibodies) in
the culture of neurons treated with 20 μM PrP1–30. Cell bodies and nu-
clei of neurons incubated with the peptide were constricted (Fig. 3B–E).
Furthermore, the peptide at 20 μM concentration caused cell death as it
is apparent from reduced density of the culture, seenunder confocalmi-
croscopy (Fig. 3B–E). Similar neurotoxic effects were obtained using
PrP1–30 lacking biotin tag (data not shown). In contrast, peptides
PrP23–32 and 23–50, lacking the signal sequence, had neither effect
on the microtubular cytoskeleton nor on the morphology of neurons
(Fig. 3G–J and Supplementary data, Fig. S3A).
Given that cytoPrP may disrupt microtubular cytoskeleton, we
sought to test whether stabilization of microtubules can suppress dele-
terious effects of PrP1–30. To this endwe employed taxol (paclitaxel), a
drug that directly binds to and irreversibly stabilizes microtubules [24].
Cortical neurons cultured for 7 days were pretreated with 100 nM taxol
for 1 h and subsequently incubatedwith 20 μMPrP1–30 in the presence
of this drug (100 nM), for the next 12 h. As it is apparent from confocal
images shown in Fig. 4, taxol protected themicrotubular cytoskeleton of
neurons from disintegration by the intracellularly localized peptide.
Taxol-treated neurons incubated with PrP1–30 retained microtubular
cytoskeleton and cellular morphology (e.g., number of neurites,
Fig. 4B) comparable to that of the control cells, cultured in the absence
of the peptide. Also, the density of taxol/PrP1–30-treated culture was
similar to that of the untreated cells.
Tau and MAP2 are known to be the physiological stabilizers of mi-
crotubules which function is negatively regulated by phosphorylation.
Previous reports have revealed that expression of exogenous Tau pro-
tein in cancer epithelial cells diminishes PrP1–30-induced disintegra-
tion of the microtubular cytoskeleton [18]. Additionally, using isolated
proteins, it has been demonstrated that phosphorylation of Tau lessens
its ability to inhibit PrP-induced aggregation of tubulin [18]. Therefore,
we decided to check whether reduction of the phosphorylation level
of MAPs in neurons may inﬂuence toxic potential of cytosolic PrP1–30.
To this end, we have used inhibitors of GSK-3 — a major kinase shown
to be responsible for phosphorylation of Tau and MAP2 [rev. in [25]].
First, we employed the aminopyrimidine derivative, CHIR98014— a se-
lective cell-permeable inhibitor of the kinase [33]. As it is shown in the
Western blots of cell lysates (Fig. 5D), treatment of neurons with 10 μM
inhibitor signiﬁcantly reduced the level of phosphorylated MAP2 and
Tau. Using confocal microscopy, we demonstrated that treatment of
the cortical aswell as hippocampal neuronswith 10 μMCHIR98014 pre-
vents loss of neurites caused by 20 μM PrP1–30 (Fig. 5A, B, C). The cells
co-treated with the inhibitor of GSK-3 and the peptide exhibitedmostly
normal morphology and unchanged microtubular cytoskeleton. At the
Fig. 3. PrP1–30 penetrates into the cytoplasm of neuronal cells and disrupts their microtubular cytoskeleton. Cortical neuronswere incubated for 12 hwith 20 μMPrP1–30 (B–E) or 20 μM
PrP23–50 (G–J), both peptides containing N-terminally attached biotin, and analyzed under a confocal microscope. Untreated neurons are shown in A and F. Localization of the peptides is
demonstrated using streptavidin-FITC (green). Staining of tubulin (red) is shown to visualize themicrotubular cytoskeleton. Additionally, in all panels nuclei are stainedwith DAPI (blue).
To demonstrate cellularmorphology,multi-layer confocal images are shown in A, B, F and G. To analyze localization of the peptides, single-layer images (Z=0.5 μm) are presented in C, D,
E andH, I, J. Panel E showsmerged images C and D,whereas panel J showsmerged H and I. In insets, magniﬁed fragments of images (single cell bodies) are demonstrated. Scale bars in the
main panels and insets represent 50 μmand 5 μm, respectively.Micrographs are representative of multiple ﬁelds frommore than ﬁve independent experiments. Note that PrP23–50 is not
localized to the cytosol and neither affects microtubular cytoskeleton nor morphology of the neurons.
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mental disorders, known to negatively regulate GSK-3-dependent
phosphorylation [rev. in [34]]. As expected, LiCl used at 10 mM concen-
tration efﬁciently decreased phosphorylation level of both MAPs in the
primary neurons (Fig. 5D). As shown in the confocal images (Fig. 5A,
B), lithium has also proven to be effective in protecting from the delete-
rious effects of PrP1–30. The cortical and hippocampal neurons
pretreated for 1 h with 10 mM LiCl and subsequently co-incubated
with the peptide (20 μM)/lithium (10mM) retained neurites and cellu-
lar morphology comparable to that of the control cells (Fig. 5A, B, C).
Since it has been previously reported that PrP fragment 106–126 in-
creases phosphorylation of MAPs in neuronal cells [22,23], we checked
whether this can also be the case for PrP1–30. As it is apparent from
theWestern blot analysis shown in Fig. 5D, PrP1–30 by itself neither af-
fected phosphorylation level of Tau nor of MAP2 in the neurons. There-
fore inﬂuence on the status of MAPs phosphorylation did not underlay
the mechanism of the above-reported PrP1–30 neurotoxicity.
To assess the inﬂuence of PrP1–30 on the viability of neurons, we
performed cytotoxicity assays based on the measurement of the lactate
dehydrogenase (LDH) released by the dead cells that have lost mem-
brane integrity. As expected from the confocal microscopy presented
above, 12-h incubationwith 20 μMPrP1–30 caused substantial increase
in the release of LDH to the culturemedia,which reﬂects reduced viabil-
ity of the neurons (Fig. 6). The cytotoxic effect of PrP1–30 was
concentration-dependent (Supplementary data, Fig. S4). At the same
time, peptides PrP23–32 and PrP23–50, lacking ability to localize to
the cytosol, had minor or no effect on the viability of neurons (Supple-
mentary data, Fig. S3B). Subsequently, we tested effect of the stabilizers
of microtubular cytoskeleton on the cytotoxicity induced by PrP1–30.
The treatments were performed as described above for immunocyto-
chemical analyses. As shown in Fig. 6A, the cells pretreated with
100 nM taxol for 1 h and subsequently co-incubated with PrP1–30/
taxol for the next 12h exhibited signiﬁcantly higher viability in compar-
ison to the neurons treated with the peptide alone. Similarly, inhibitors
of MAPs phosphorylation — CHIR98014 and LiCl increased viability of
the PrP1–30-treated cells (Fig. 6B). Treatment of the neurons with10 μM CHIR98014 caused substantial decrease in the amount of dead
cells. The cells treatedwith LiCl in the range of 1–10mMconcentrations
and subsequently co-treated with PrP1–30/LiCl exhibited viability
comparable to that of the control neurons (Fig. 6C).
Dendritic spines are actin-rich postsynaptic structures, stabilized by
the actin cytoskeleton. Nevertheless, studies from recent years have
provided convincing evidence for important role of themicrotubular cy-
toskeleton in the formation and maintenance of these structures [36].
Importantly, loss of dendritic spines has been reported previously in an-
imal model of TSE [37]. Therefore, we decided to check whether PrP1–
30 may affect stability of dendritic spines on the primary neurons
(Fig. 7). The cortical neurons were cultured for 3 weeks to form the
spines and subsequently treated with 20 μM PrP1–30 for 12 h. Before
the treatments the neurons were transfected with plasmid encoding
RFP to visualize dendritic protrusions. Although infrequent, only these
peptide-treated cells that retained neurites were selected for further
analysis. Plausibly, these neurons represent cells at the early stages of
peptide-caused degeneration. Also, it seems that the neurons cultured
for 3 weeks are less susceptible to PrP1–30 than the one-week culture.
This may be explained by the elevated level of GSK-3 in the developing
rat brain, which peaked around postnatal day 10 and then gradually de-
creased [32]. As it is shown in confocal micrographs in Fig. 7, PrP1–30
caused considerable reduction in the number of dendritic spines. The
loss of the spines was apparent from the samples stained with RFP, as
well as with antibodies against synaptophysin, a synaptic marker. In
linewith the above observations, we found that stabilizers of themicro-
tubular cytoskeleton were also effective in protecting dendritic spines
from cytosolic PrP1–30. The neurons treated with either 100 nM taxol
or 10 mM LiCl appeared less vulnerable to PrP1–30 and retained higher
density of dendritic spines than the cells treated with the peptide alone
(Fig. 7).
Loss of plasma membrane integrity provides a measure of cellular
viability irrespective of the type of cell death. Hence, to discriminate
between apoptosis and necrosis in the PrP1–30-treated culture, we per-
formed analyses using antibodies against cleaved caspase-3, amarker of
apoptotic cell death. Immunocytochemical analysis shown in Fig. 8
Fig. 4. Stabilization ofmicrotubular cytoskeleton prevents PrP1–30-inducedmorphological changes of neurons. (A) Confocal microscopy of the cortical neurons incubated for 12 hwith or
without 20 μM PrP1–30. To stabilize the microtubular cytoskeleton the cells were pretreated with 100 nM taxol for 1 h and subsequently incubated with this drug for the next 12 h.
Stainings for tubulin (red) and nuclei (DAPI, blue) are shown. The presented micrographs are representative for at least three separate experiments. The mean numbers (±S.E., n = 3)
of neurites (with the length of at least 50 μm) per cell are presented in (B).
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ture treatedwith the peptide. As low as 0.7%± 0.6 (mean± S.E., n= 3)
of PrP1–30-treated cells were positive for the apoptotic marker, though
numerous dead cells were observed (see below). Similar faint staining
with antibodies against activated caspase-3 was obtained for untreated
neurons (1.5% ± 0.9 of apoptotic cells; mean± S.E., n = 3). In contrast,
exposition of the culture to doxorubicin, a known inducer of apoptosis,
signiﬁcantly increased the level of activated caspase-3 up to 26% ± 1.8
of positively stained cells (mean ± S.E., n = 3). This was accompanied
by nuclear condensation and fragmentation, also typical for apoptotic
cell death. At the same time, employing trypan blue exclusion test, in
the peptide-treated culture we detected 2.3 ± 0.2 (mean ± S.E., n =
3) timesmore dead cells than in the untreated control. Since nomarkers
of necrotic cell death have been identiﬁed yet, and only negative
markers are available, the increase in the amount of dead cells accompa-
nied by barely detectable level of activated caspase-3 in the neuronal
culture exposed to PrP1–30 suggests induction of necrosis.
Given that lithium has been shown to induce autophagy, thereby
leading to the clearance of aggregated PrP in TSE-infected cells [35],
we checked whether this mechanism was also employed in the neuro-
protection from PrP1–30. Activation of autophagy is reﬂected by the
conversion of cytosolic microtubule-associated protein 1 light chain 3
(LC3-I) intomembrane-associated LC3-II (of higher electrophoreticmo-
bility), which is used as an autophagy marker. Therefore, we checked
the levels of both LC3 forms in the neurons treated with LiCl for the
time (1h+12h) allowing inhibition of PrP1–30-induced neurotoxicity.As shown in Fig. 9, LiCl even at 10 mM concentration has not affected
the ratio of the LC3 forms which indicates that the mechanism of the
above-reported protective action of lithium is not related to the
autophagy.
4. Discussion
Since the brain tissue of PrP-deﬁcient animals is not damaged by
PrPSc, it has been postulated that infectious and toxic agent in TSE
might be two separate entities [38]. While PrPSc is widely presumed to
be a particle transmitting disease, the nature of neurotoxic species re-
mains obscure. As a plausible candidate, cytoPrP has been proposed
[rev. in [9]]. Substantial raise in the concentration of cytoPrP has been
reported in familial forms of TSE. Toxic effects of cytosolic accumulation
of PrP have been observed both in cell cultures [39,40] and inmodel an-
imals [39,41]. CytoPrP has been shown to reduce viability of neuroblas-
toma cells as well as some non-neuronal cells [39,40]. Furthermore,
progression of neurodegeneration in the patients with familial TSE
and transgenic animals is linked to increased synthesis of CtmPrP, a
transmembrane formwith onlyN-terminal domain residing in the cyto-
sol [5,42,43]. Transgenic mice expressing PrP mutant which entirely ac-
cumulates in the cytosol develop severe degeneration of cerebellar
neurons [39]. Mislocalized PrP is also able to cause toxicity in forebrain
neurons [41]. Subsequently, a region-speciﬁc neurodegeneration in the
brain of cytoPrP-expressingmice has been reported,where pathological
alterations varied among cerebellum, hippocampus and neocortex [44].
Fig. 5. Reduction of GSK-3-dependent phosphorylation of MAPs prevents PrP1–30-inducedmorphological changes of neurons. Confocal microscopy for the cortical (A) and hippocampal
(B) neurons incubated for 12hwith orwithout 20 μMPrP1–30. To stabilize themicrotubular cytoskeleton the cellswere pretreated for 1 hwith inhibitors of GSK–3: CHIR98014 (10 μM)or
LiCl (10mM) and subsequently incubatedwith these agents for the next 12 h. Stainings for tubulin (red) and nuclei (DAPI, blue) are shown. Themean numbers (±S.E., n= 3) of neurites
(with the length of at least 50 μm) per cell are presented in (C). (D)Western blots for the lysates of untreated cortical neurons and treated as abovewith CHIR98014 and LiCl, probedwith
antibodies against Tau, phosphorylated Tau (pTau),MAP2 andphosphorylatedMAP2 (pMAP2). Additionally, the level ofMAPs phosphorylation in the neurons treatedwith PrP1–30 alone
is presented. The increased electrophoretical mobility of Tau reﬂects reduced phosphorylation level of the protein in CHIR98014-, as well as LiCl-treated neurons. This is also conﬁrmed
using antibodies against phosphorylated Tau. Reduction of the level of pMAP2 in the cells treated with the inhibitors of GSK-3 is compared with the level of total MAP2. The presented
results are representative for at least three independent experiments.
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toxic to the cortical as well as hippocampal primary neurons isolated
from rat embryos.
Despite many efforts, themechanism of the neurotoxicity caused by
cytoPrP is still unresolved. It has been postulated that this toxicity is
directly linked to the interactions with intracellular proteins which
are not physiological partners of PrP. It appears that one of the
consequences of PrP mislocalization in the cytosol might be a direct in-
teraction with tubulin, leading to the loss of its function in the microtu-
bular cytoskeleton and eventually cell death [rev. in [11]]. The recent
years of studies have provided numerous reports evidencing association
of PrP with tubulin andmicrotubules [12,45,46]. Importantly, this inter-
action has been demonstrated to be deleterious to the cell [16]. It has
been shown that PrP induces oligomerization/aggregation of tubulin,
which inhibits formation of microtubules [15]. The major tubulin-
binding site, responsible for inhibition of microtubule assembly, hasbeen identiﬁed within residues 23–32 of the PrP molecule [16]. Accord-
ingly, cell-penetrating peptide composed of the N-terminal signal se-
quence 1–22 and residues 23–30 has been shown to disintegrate the
microtubular cytoskeleton of epithelial cells [16]. Similar peptide,
namely PrP1–28 induces morphological changes and toxicity in neuro-
blastoma N2a cells, however the mechanism of its action has not been
analyzed [30]. We have also found that PrP impairs kinesin-driven
transport alongmicrotubules and cell-penetrating PrP1–30 induces for-
mation of aberrant mitotic spindles in tumor PC-12 cells [47]. In the
present report, we have demonstrated that intracellularly localized
PrP1–30 disrupts the microtubular cytoskeleton of primary neurons
leading to loss of neurites and necrotic cell death. For the ﬁrst time,
we have shown here that the N-terminal fragment of cytoPrP causes
loss of dendritic spines, synaptic structures crucial for learning and
memory. Interestingly, it was previously reported that one of the earli-
est pathological changes observed in TSE-infected animals involved
Fig. 6. Stabilization of microtubular cytoskeleton increases viability of PrP1–30-treated neurons. Viability of the cortical neurons incubated for 12 h with or without 20 μM PrP1–30 was
assessed by the release of LDH to the culture media. To stabilize microtubular cytoskeleton the cells were treated with 100 nM taxol (A) or with the agents reducing activity of GSK-3:
10 μM CHIR98014 and 10 mM LiCl (B). Dose-dependent effect of LiCl on the viability of the peptide-treated neurons is shown in (C). In all panels, the effect of the peptide is expressed
as the ratio of LDH released by the peptide-treated and untreated cells. Error bars represent S.E., n = 3.
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dritic spines have been shown in recent studies to be also dependent on
intact microtubular cytoskeleton [36,48]. It is plausible that induced by
cytoPrP aberration ofmicrotubule dynamics, disruption ofmicrotubular
cytoskeleton and deﬁciency in microtubule-dependent transport may
affect formation and stability of the spines. Thus, our results provide
compelling evidence for important role of microtubules in these synap-
tic structures.
Our results indicate that stabilization of microtubules may protect
neurons from neurotoxic effects of cytoPrP. In the cell, themicrotubular
cytoskeleton is stabilized by MAPs such as Tau and MAP2. In the previ-
ous studies, employing isolated proteins we have demonstrated that
crude fraction of MAPs as well as puriﬁed Tau inhibit PrP-induced ag-
gregation of tubulin [18]. This observation has been conﬁrmed on the
cellular level by demonstrating that expression of exogenous Tau in ep-
ithelial cells reduces deleterious effects of PrP1–30. In the present re-
port, we employed taxol, an antineoplastic drug known to speciﬁcally
stabilize microtubules and promote their assembly [24]. Expectedly,
treatment with this stabilizer protected neurons from toxicity caused
by intracellularly localized PrP1–30. Taxol-treated cells appeared less
vulnerable to PrP1–30-induced disassembly of microtubular cytoskele-
ton, loss of dendritic spines and neurites, and necrosis. This clearlyindicates that neurotoxicity exerted by cytoPrPmay be linked to disrup-
tion of the microtubular cytoskeleton. Although used as a potent che-
motherapeutic in multiple types of cancer, taxol is not suitable drug
candidate for treatment of neurodegenerative diseases due to its rela-
tively high neurotoxicity [49] and restricted penetration into the brain
[50,51].
Stabilization of microtubules by MAPs is negatively regulated by
phosphorylation, and GSK-3 has been identiﬁed as a major kinase re-
sponsible for this modiﬁcation, and hyperphosphorylation of Tau in
neurodegenerative diseases [rev. in [25]]. Noteworthy, elevated level
of Tau phosphorylation has been amply reported in brains of TSE pa-
tients and animals experimentally infected with PrPSc [19–21,52,53].
Additionally, it has been demonstrated that exposure of neurons to am-
yloid aggregates of PrP106–126 leads to increase of GSK-3 activity re-
sulted in hyperphosphorylation of Tau and MAP2 [22]. It has also been
reported for isolated proteins that elevated level of Tau phosphorylation
reduces its ability to protect tubulin from PrP-induced aggregation [18].
Thus, in light of our observations, reduction of GSK-3 activity appears a
promising approach in TSE therapy. In the present study, we have
shown that inhibition of GSK-3 leading to the reduction of MAPs phos-
phorylation suppresses loss of dendritic spines and neurites, and in-
creases viability of the neurons exposed to PrP1–30. Used herein
Fig. 7. PrP1–30 induces loss of dendritic spines. (A) Confocal microscopy of the cortical neurons cultured for 23 days and subsequently incubated for 12 hwith or without 20 μMPrP1–30.
To check the effect ofmicrotubule stabilization, the cells were pretreated for 1 hwith 100 nMtaxol or 10mMLiCl and subsequently incubatedwith these compounds for the next 12 h. The
cells were transfected (on day 21)with plasmid encoding RFP (white) to visualize dendritic protrusions and stainedwith antibodies against synaptophysin (green) to identify presynaptic
terminals. Presented images are representative of at least 150 transfected cells. Density of dendritic spines was assessed on the primary branches of dendrites. (B) The mean numbers
(±S.E., n = 3) of spines per 50 μm of dendritic length.
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LiCl [[33], rev. in [34]], effectively protected from PrP1–30 toxicity. It has
been previously demonstrated that LiCl and CHIR98014 reduce phos-
phorylation of Tau in the hippocampus and cortex of postnatal rats
[54]. Thus, both inhibitors appear of potential use in the treatment of
cytoPrP-related neurodegenerative conditions. However, high potency
of CHIR98014 in GSK-3 inhibition has been recently shown to beaccompanied by a considerable toxicity in the culture of embryonic
stem cells [55]. Given the well-documented and relatively safe usage
of lithium salts in human therapy, in our opinion, this drug deserves
more attention than CHIR98014.
Lithium is known for its pleiotropic action including inhibition of
phosphoesterases, phosphoglucomutase, adenylyl cyclase, NMDA (N-
methyl-D-aspartate) receptor channel and GSK-3 [rev. in: [34,56–58]].
Fig. 8. PrP1–30 induces non-apoptotic death of neuronal cells. Confocal microscopy of the cortical neurons incubated for 12 hwith or without 20 μMPrP1–30. The cells were stained with
antibodies against active caspase-3 (green) to identify apoptotic cells. Staining of tubulin (red) and nuclei (DAPI, blue) is also shown. Doxorubicin (25 nM)was used to induce apoptosis in
the positive control. To assess the number of apoptotic cells, ﬁve to seven randomly chosen microscopic ﬁelds per coverslip were analyzed (~150 cells per coverslip).
2237T. Zajkowski et al. / Biochimica et Biophysica Acta 1853 (2015) 2228–2239At low doses (~1 mM), this monovalent cation inhibits inositol
monophosphatasewhich, in turn, affects phosphatidylinositol signaling,
andmay result in activation of autophagy [[59], rev. in [34]]. In contrast,
at higher concentrations lithium can suppress autophagosomeFig. 9. Protective effect of lithium is not related to autophagy. Western blot for the lysates
of cortical neurons treated and untreated with 10 mM LiCl, analyzed with antibodies
against LC3. The cells were incubated with LiCl for 13 h (in total), as in all other experi-
ments. As a positive control, lysate of the breast cancer cells MCF-7 treated with melato-
nin — an autophagy inducer is shown in the right panel. Level of β-actin in each lane is
demonstrated as a loading control.formation through inhibition of GSK-3 [60]. Given that overactivation
of GSK-3 has been implicated in diverse neuropathological conditions,
this kinase is believed to be the main target of neuroprotective action
of lithium. This cation can inhibit GSK-3 directly by competing for its
magnesium-binding site and indirectly by inducing inhibitory phos-
phorylation of the kinase, mediated through phosphatidylinositol 3-
kinase/AKT pathway. Additionally, lithium down-regulates expression
of GSK-3 gene [61]. Furthermore, by inhibiting NMDA receptor-
mediated calcium inﬂux, lithium inﬂuences calcium homeostasis [58].
In turn, reduction of intracellular calciumconcentration decreases activ-
ity of calpain and thusmay also suppress calpain-mediated activation of
GSK-3 [62]. Formore that half a century, lithium salts have been used in
the treatment of psychoses such as bipolar disorder. Accumulating evi-
dence indicates that this mood stabilizermay be useful in the treatment
of multiple neurologic and even neurodegenerative diseases. Beneﬁcial
effects of lithium have been reported in animal models of CNS disorders
including Alzheimer disease, amyotrophic lateral sclerosis as well as
Huntington and Parkinson diseases [rev. in [56]]. Based on its neuropro-
tective and neurotrophic properties, a potential application of lithium in
the treatment of TSE in livestock has been previously speculated in
theoretical papers [63]. In line with the abovementioned hypothesis,
lithiumhas been shown to inhibit neuronal cell death induced by aggre-
gates of PrP peptide 106–126 [22]. It has also been reported that
lithium-induced autophagy leads to the clearance of PrPSc in TSE-
infected cells [35]. Our study provides experimental evidence that lith-
iummay protect neurons from the toxicity caused by cytoPrP, which el-
evated level is observed in some TSE. The results presented here imply
that stabilization of the microtubular cytoskeleton through reduction
of MAPs phosphorylation may be a promising target in the therapy of
these neurodegenerative diseases. Taken together, lithium appears to
be effective both in inhibition of spreading of TSE infectious particles
and protection from neurodegeneration exerted by cytotoxic species
in TSE. Future studies in animal models of TSE are clearly required to
assess the therapeutic potential of lithium.
2238 T. Zajkowski et al. / Biochimica et Biophysica Acta 1853 (2015) 2228–2239Supplementary data to this article can be found online at http://dx.
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